Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
1400 Results for "
Reversible
" in MedChemExpress (MCE) Product Catalog:
Products (1400)
1400 Results for "Reversible" in MCE Product Catalog:
Cat. No.: HY-133178R
CAS No.: 131086-98-1
Synonyms: 3,4,8,9-Tetrahydroxy urolithin (Standard)
Category:
Target:
Target:
Research Areas:
α1A-AR Degrader 9c is a potent, selective and reversible α1A-AR (Adrenergic receptor) PROTAC degrader, with a DC50 of 2.86 μM. α1A-AR Degrader 9c induces α1A-AR degradation can be attributed to proteasomal degradation. α1A-AR Degrader 9c inhibits the proliferation of PC-3 cells, with an IC50 of 6.12 μM. α1A-AR Degrader 9c shows antitumor activity, and can be used for prostate cancer research .
Cat. No.: HY-156052
CAS No.: 2077164-48-6
Target:
Research Areas:
CN-716 dihydrochloride is a reversible covalent flavivirus NS2B·NS3 protease inhibitor with antiviral activity. CN-716 dihydrochloride effectively inhibits the replication of dengue virus (DENV2), West Nile virus (WNV) and Zika virus (ZIKV). The IC50 values of CN-716 dihydrochloride against the proteases of the above three viruses are 0.066 μM, 0.11 μM and 0.25 μM, respectively, while the Ki values against the same proteases are 0.051 μM, 0.082 μM and 0.04 μM, respectively. CN-716 dihydrochloride can be used to study the infection mechanisms of dengue fever, West Nile fever and Zika virus infection .
Cat. No.: HY-158252S
CAS No.: 1253297-72-1
Synonyms: NO050328-d5 hydrochloride; NO328-d5 hydrochloride; TGB-d5 hydrochloride
Cat. No.: HY-161275
CAS No.: 2769715-68-4
Target:
Research Areas:
BI-4732 is an orally active, reversible, ATP-competitive EGFR inhibitor with blood-brain barrier penetration. BI-4732 inhibits the kinase activity of EGFR L858R, T790M and C797S with IC50 values of 1 nM while sparing EGFR wild-type. BI-4732 inhibits EGFR and reduces the phosphorylation of AKT, ERK, and S6K. BI-4732 demonstrates excellent intracranial anti-tumor efficacy in YU-1097 xenograft model harboring EGFR_E19del/T790M/C797S. BI-4732 can be used for the study of non-small cell lung cancer (NSCLC) .
Cat. No.: HY-170921
Target:
Research Areas:
USP1-IN-11 (compound 38-P2) is a selective, reversible, and noncompetitive USP1 (Ubiquitin-specific protease 1) inhibitor. USP1-IN-11 activates the DDR (DNA damage repair) pathway, induces cell cycle arrest and cell Apoptosis, and inhibits cell survival. USP1-IN-11 enhances the sensitivity of Olaparib (HY-10162)-resistant cells to Olaparib (HY-10162) and shows a synergetic effect with Andrographolide (HY-N0191) in BRCA-proficient cancer cells. USP1-IN-11 displays significant, dose-dependent antitumor efficacy in the MDA-MB-436 xenograft model .
Cat. No.: HY-175177
Xiap-casp7 PPI-IN-1 is a reversible XIAP: CASP7 inhibitor with specifically disrupting the interaction between XIAP and CASP7. XIAP-CASP7 PPI-IN-1 selectively induce MCF-7 and other caspase-3 down-regulation (CASP3/DR) triple-negative breast cancer cell apoptosis. XIAP-CASP7 PPI-IN-1 overcomes chemoresistance via down-regulating β-catenin and its associated ABC transporters in Paclitaxel (HY-B0015)-resistant MCF-7 cells. XIAP-CASP7 PPI-IN-1 can be used for the study of breast cancer .
Cat. No.: HY-182373
CAS No.: 850033-84-0
Target:
Research Areas:
5-HT2C agonist-13 is an orally active, selective and brain-penetrant 5-HT2C receptor agonist with human 5-HT2C receptor EC50 of 16 nM, Ki of 20 nM. 5-HT2C agonist-13 functionally activates 5-HT2C receptors, reduces food intake, reduces body weight gain, and exhibits effects reversible by a selective 5-HT2C antagonist. 5-HT2C agonist-13 can be used for the research of obesity .
Cat. No.: HY-184870
CAS No.: 31621-87-1
Target:
Research Areas:
Polydioxanone is a colorless, crystalline semi-crystalline thermoplastic poly (ether-ester) bioabsorbable polymer. Polydioxanone serves as a hemostatic agent, biodegradable agent, degradant, lumen patency maintainer, as well as a temporary inducer of tracheal tissue injury and inflammation. Polydioxanone controls bone bleeding in biocompatible matrices, degrades via random hydrolytic scission and end-chain scission, with accelerated degradation occurring at pH <1.67, maintains tracheal lumen patency, and induces reversible tracheal epithelial necrosis, inflammation, fibrous tissue hyperplasia, and goblet cell hyperplasia. Polydioxanone can be used in research on bone bleeding, non-malignant tracheal stenosis, tracheobronchial stenosis, tracheobronchomalacia, and airway obstruction associated with vascular compression .
Cat. No.: HY-185274
CAS No.: 219607-49-5
Target:
Research Areas:
3'-O-(2-Nitrobenzyl)-dTTP acts as a reversible terminator for DNA chain elongation. 3'-O-(2-Nitrobenzyl)-dTTP interacts with 9°N polymerase (exo-) A485L/Y409V, gets recognized and incorporated into the elongating DNA chain, thereby temporarily terminating the polymerase reaction. 3'-O-(2-Nitrobenzyl)-dTTP carries a 3'-O-(2-nitrobenzyl) blocking group, which can be removed by laser irradiation to regenerate the free 3'-OH − group and restore polymerase activity. 3'-O-(2-Nitrobenzyl)-dTTP is applicable in DNA sequencing studies .
Cat. No.: HY-187687
CAS No.: 2740603-37-4
Target:
Ferroptosis Fatty Acid Synthase (FASN) Keap1-Nrf2 Glutathione Peroxidase Reactive Oxygen Species (ROS)
Research Areas:
Anticancer agent 359 is a ferroptosis inducer. Anticancer agent 359 inhibits the proliferation, colony formation and migration of bladder cancer cells in a concentration-dependent manner. Anticancer agent 359 induces ferroptosis by downregulating SREBP1 to inhibit FASN transcription, reducing the expression of NRF2/SLC7A11/GPX4, decreasing GSH, promoting ROS accumulation and lipid peroxidation; this effect is reversible by Ferrostatin-1 (HY-100579). Anticancer agent 359 acts synergistically with Talazoparib (HY-16106). Anticancer agent 359 inhibits tumor growth in vivo without obvious hepatotoxicity or nephrotoxicity. Anticancer agent 359 can be used in the research of bladder cancer .
Cat. No.: HY-B0653AS
Synonyms: (S)-(–)-Bupivacaie-d9hydrochloride
Cat. No.: HY-B0879AR
CAS No.: 129-46-4
Synonyms: Suramin hexasodium salt (Standard)
Target:
Reference Standards Phosphatase Sirtuin Reverse Transcriptase Topoisomerase SARS-CoV Parasite Apoptosis
Research Areas:
Suramin (sodium salt) (Standard) is the analytical standard of Suramin (sodium salt). This product is intended for research and analytical applications. Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor . Suramin sodium salt is a potent inhibitor of sirtuins: SirT1 (IC50=297 nM), SirT2 (IC50=1.15 μM), and SirT5 (IC50=22 μM) . Suramin sodium salt is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC50=5 μM) . Suramin sodium salt is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor . Suramin sodium salt efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent .
Target:
Research Areas:
Antazoline hydrochloride is a histamine H1 receptor antagonist with anticholinergic and antiviral properties. Antazoline hydrochloride can prevent histamine from acting on target cells through a reversible competition effect on histamine receptor sites of these cells. Antazoline hydrochloride can exert an antiallegic effect and prevent the occurrence of physiological reactions from the effect of blocking as well as inhibiting H1 receptor. Antazoline hydrochloride can effectively reduce HBV DNA in the extracellular supernatant in a dose-dependent manner, with EC50 of 2.910 μmol/L in HepAD38 cells. Antazoline hydrochloride also has a significant inhibitory effect on HBV DNA in the extracellular supernatant of Huh7 cells (EC50 = 2.349 μmol/L). Antazoline hydrochloride has anti-arrhythmic effect in acute myocardial infarctions. Antazoline hydrochloride can be studied in research for cardiovascular diseases, and HBV .
Target:
Research Areas:
6-Methoxyflavanone (6-MeOF) is a flavonoid compound that can cross the blood-brain barrier. 6-Methoxyflavanone is a positive allosteric modulator of GABAA receptors. 6-Methoxyflavanone exhibits positive allosteric regulatory effects on human recombinant α1β2γ2L and α2β2γ2L GABAA receptors, and is relatively inactive on the α1β2 GABAA receptor. 6-Methoxyflavanone showes inhibitory behavior towards the activation of bitter receptor hTAS2R39 and hTAS2R14, demonstrating a reversible and non-overcome antagonistic effect. 6-Methoxyflavanone has the effects of anti-anxiety, analgesia and relief of neuropathic pain .
Cat. No.: HY-P0037
CAS No.: 136208-71-4
Synonyms: Org 30850ANT
Target:
Research Areas:
Synonyms: GPDH, rabbit muscle; α-Glycerophosphate dehydrogenase, rabbit muscle; Glycerol phosphate dehydrogenase, rabbit muscle
Target:
Research Areas:
Glycerol‑3‑phosphate dehydrogenase, rabbit muscle (GPDH; α-Glycerophosphate dehydrogenase; Glycerol phosphate dehydrogenase) is an NADH-dependent oxidoreductase derived from rabbit muscle that participates in glycolysis, gluconeogenesis, and the glycerol‑3‑phosphate shuttle metabolic pathway. Glycerol‑3‑phosphate dehydrogenase, rabbit muscle uses NADH as a reducing equivalent donor, and its substrate binding relies on the phosphate-binding site in the active center; it catalyzes the reversible reduction of dihydroxyacetone phosphate to L‑α‑glycerol‑3‑phosphate. The catalytic activity of the enzymatic reaction of Glycerol‑3‑phosphate dehydrogenase, rabbit muscle is regulated by pH and divalent metal ions. Glycerol‑3‑phosphate dehydrogenase, rabbit muscle can be used in metabolism-related studies .
Synonyms: EC 2.6.1.1, porcine heart; GOT, porcine heart; AST, porcine heart
Research Areas:
Aspartate aminotransferase (EC 2.6.1.1), porcine heart is a metabolic regulator with the highest activity in the heart, liver and skeletal muscle. Aspartate aminotransferase, porcine heart comprises two isozymes: the cytoplasmic form (AST1) and the mitochondrial form (AST2). By catalyzing reversible transamination reactions between oxaloacetate, L-glutamate and other substances, it is deeply involved in key physiological processes such as amino acid metabolism, the tricarboxylic acid cycle and neurotransmitter synthesis. Aspartate aminotransferase, porcine heart also provides substrate support for the synthesis of urea and purines/pyrimidines. Aspartate aminotransferase, porcine heart is a serum marker reflecting cardiac and hepatic injury, and its abnormal levels are also closely associated with myocardial infarction, cardiovascular diseases and various cancers .
Synonyms: EC 2.6.1.1, Human liver; GOT, Human liver; AST, Human liver
Research Areas:
Aspartate aminotransferase (EC 2.6.1.1), Human liver is a metabolic regulator with the highest activity in the heart, liver and skeletal muscle. Aspartate aminotransferase, Human liver comprises two isozymes: the cytoplasmic form (AST1) and the mitochondrial form (AST2). By catalyzing reversible transamination reactions between oxaloacetate, L-glutamate and other substances, it is deeply involved in key physiological processes such as amino acid metabolism, the tricarboxylic acid cycle and neurotransmitter synthesis. Aspartate aminotransferase, Human liver also provides substrate support for the synthesis of urea and purines/pyrimidines. Aspartate aminotransferase, Human liver is a serum marker reflecting cardiac and hepatic injury, and its abnormal levels are also closely associated with myocardial infarction, cardiovascular diseases and various cancers .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
